Regencor Inc

Leading Innovators in Cardiac Muscle Regeneration 2021

Regencor has discovered and patented a recombinant glycosylation variant of a normal circulating human protein, Follistatin Like-1, that dramatically regenerates the heart after a heart attack (Nature 24 September 2015). Additional pig studies have shown that the protein is active in both the acute MI setting (6.2 M patients/year WW), and the chronic heart failure setting (29 M patients WW). The protein is formulated in a depot preparation delivered by sub cutaneous injection as an outpatient.